Phase I trial of oral fenretinide in children with high-risk solid tumors: A report from the children's oncology group (CCG 09709)

Journal of Clinical Oncology

Volumn 24, Issue 21, 2006, Pages 3423-3430

  Villablanca, Judith G ^a   Krailo, Mark D ^a   Ames, Matthew M ^a   Reid, Joel M ^a   Reaman, Gregory H ^a   Reynolds, Patrick C ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; ANTINEOPLASTIC AGENT; FENRETINIDE; ISOTRETINOIN; N (4 METHOXYPHENYL)RETINAMIDE; N 4 HYDROXYPHENYLRETINAMIDE; RETINOL DERIVATIVE; UNCLASSIFIED DRUG; RETINOL;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN PSEUDOTUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG WITHDRAWAL; DRY EYE; DRY SKIN; EWING SARCOMA; FEMALE; GLIOMA; HEPATOBLASTOMA; HIGH RISK PATIENT; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOALBUMINEMIA; HYPOPHOSPHATEMIA; LEUKOCYTE COUNT; LIVER GRAFT; LUNG SARCOMA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MEDULLOBLASTOMA; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROBLASTOMA; NEUROBLASTOMA; OSTEOSARCOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOLID TUMOR; THROMBOCYTE COUNT; TREATMENT RESPONSE; VOMITING; BLOOD; DRUG ADMINISTRATION; NEOPLASM; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FENRETINIDE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; NEUROBLASTOMA; TREATMENT OUTCOME; VITAMIN A;

EID: 33746799839     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.9271     Document Type: Article

References (58)

1. Gudas LJ, Sporn MB, Roberts AB: Cellular biology and biochemistry of the retinoids, In Sporn MB, Roberts AB, Goodman DS (eds): The Retinoids. New York, NY, Raven Press, 1994, pp 443-520
2. Reynolds CP, Matthay KK, Villablanca JG, et al: Retinoid therapy of high-risk neuroblastoma. Cancer Lett 197:185-192, 2003
3. Reynolds CP, Wang Y, Melton LJ, et al: Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide. Med Pediatr Oncol 35:597-602, 2000
4. Di Vinci A, Geido E, Infusini E, et al: Neuroblastoma cell apoptosis induced by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. Int J Cancer 59:422-426, 1994
5. Mariotti A, Marcora E, Bunone G, et al: N-(4-hydroxyphenyl) retinamide: A potent inducer of apoptosis in human neuroblastoma cells. J Natl Cancer Inst 86:1245-1247, 1994
6. Ponzoni M, Bocca P, Chiesa V, et al: Differential effects of N-(4-hydroxyphenyl) retinamide and retinole acid on neuroblastoma cells: Apoptosis versus differentiation. Cancer Res 55:853-861, 1995
7. Ziv Y, Gupta MK, Milsom JW, et al: The effect of tamoxifen and fenretinimide on human colorectal cancer cell lines in vitro. Anticancer Res 14:2005-2009, 1994
8. Hsieh TC, Ng C, Wu JM: The synthetic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR) exerts antiproliferative and apoptosis-inducing effects in the androgen-independent human prostatic JCA-1 cells. Biochem Mol Biol Int 37:499-506, 1995
9. Kazmi SM, Plante RK, Visconti V, et al: Comparison of N-(4-hydroxyphenyl) retinamide and all-trans-retinoic acid in the regulation of retinoid receptor-mediated gene expression in human breast cancer cell lines. Cancer Res 56:1056-1062, 1996
10. Pellegrini R, Mariotti A, Tagliabue E, et al: Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4-hydroxyphenyl) retinamide. Cell Growth Differ 6:863-869, 1995
11. Sheikh MS, Shao ZM, Li XS, et al: N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Carcinogenesis 16:2477-2486, 1995
12. Supino R, Crosti M, Clerici M, et al: Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinole acid receptor expression. Int J Cancer 65:491-497, 1996
13. Kalemkerian GP, Slusher R, Ramalingam S, et al: Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines. J Natl Cancer Inst 87:1674-1680, 1995
14. Dipietrantonio AHT, Wu JM: Differential effects of retinole acid (RA) and N-(4-hydroxyphenyl) retinamide (4-HPR) on cell growth, induction of differentiation, and changes in p34cdc2, Bcl-2, and actin expression in the human promyelocytic HL-60 leukemic cells. Biochem Biophys Res Commun 224: 837-842, 1996
15. Delia D, Aiello A, Lombardi L, et al: N-(4-hydroxyphenyl) retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 53:6036-6041, 1993
16. Maurer BJ, Metelitsa LS, Seeger RC, et al: Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)-retinamide in neuroblastoma cell lines. J Natl Cancer Inst 91: 1138-1146, 1999
17. Batra S, Reynolds CP, Maurer BJ: Fenretinide cytotoxicity for Ewing's sarcoma (ES) and primitive neuroectodermal tumor (PNET) cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators. Cancer Res 64:5415-5424, 2004
18. Fanjul AN, Delia D, Pierotti MA, et al: 4-hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J Biol Chem 271: 22441-22446, 1996
19. Sani BP, Shealy YF, Hill DL: N-(4-hydroxyphenyl) retinamide: Interactions with retinoid-binding proteins/ receptors. Carcinogenesis 16:2531-2534, 1995
20. Liu G, Wu M, Levi G, et al: Inhibition of cancer cell growth by all-trans retinole acid and its analog N-(4-hydroxyphenyl) retinamide: A possible mechanism of action via regulation of retinoid receptors expression. Int J Cancer 78:248-254, 1998
21. Maurer BJ, Melton L, Billups C, et al: Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl) retinamide and modulators of ceramide metabolism. J Natl Cancer Inst 92:1897-1909, 2000
22. Wang H, Maurer BJ, Reynolds CP, et al: N-(4-hydroxyphenyl) retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase. Cancer Res 61:5103-5105, 2001
23. Reynolds C, Maurer BJ, Kolesnik RN: Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett 206:169-180, 2004
24. Oridate N, Suzuki S, Higuchi M, et al: Involvement of reactive oxygen species in N-(4-hydroxyphenyl) retinamide-induced apoptosis in cervical carcinoma cells. J Natl Cancer Inst 89:1191-1198, 1997
25. Ribatti D, Alessandri G, Baronio M, et al: Inhibition of neuroblastoma-induced angiogenesis by fenretinide. Int J Cancer 94:314-321, 2001
26. Erdreich-Epstein A, Tran LB, Bowman NN, et al: Ceramide signaling in fenretinide-induced endothelial cell apoptosis. J Biol Chem 277:49531-49537, 2002
27. Pienta KJ, Nguyen NM, Lehr JE: Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. Cancer Res 53:224-226, 1993
28. Villa ML, Ferrario E, Trabattoni D, et al: Retinoids, breast cancer and NK cells. Br J Cancer 68: 845-850, 1993
29. Abou-Issa H, Curley RW Jr, Panigot MJ, et al: In vivo use of N-(4-hydroxyphenyl retinamide)-0-glucuronide as a breast cancer chemopreventive agent. Anticancer Res 13:1431-1436, 1993
30. Cope MB, Steele VE, Lubet RA, et al: Efficacy of 9-cis-retinoid acid and N-(4-hydroxyphenyl) retinamide alone and in combination in mammary cancer prevention. Oncol Rep 11:465-469, 2004
31. Slawin K, Kadmon D, Park SH, et al: Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras+ myc-induced carcinomas in the mouse prostate reconstitution model system. Cancer Res 53:4461-4465, 1993
32. Formelli F, Cleris L: Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res 53:5374-5376, 1993
33. Gopal AK, Pagel JM, Hedin N, et al: Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism. Blood 103:3516-3520, 2004
34. Torrisi R, Parodi S, Fontana V, et al: Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid fenretinide in breast cancer patients. Cancer Epidemiol Biomarkers Prev 3:507-510, 1994
35. DePalo G, Veronesi U, Marubini E, et al: Controlled clinical trials with fenretinide in breast cancer, basal cell carcinoma and oral leukoplakia. J Cell Biochem 22:11-17, 1995 (Suppl)
36. Cobleigh MA, Dowlatshahi K, Deutsch TA, et al: Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer. J Clin Oncol 11:474-477, 1993
37. Costa A, Malone W, Perloff M, et al: Tolerability of the synthetic retinoid fenretinide (HPR). Eur J Cancer Clin Oncol 25:805-808, 1989
38. Kaiser-Kupfer MI, Peck GL, Caruso RC, et al: Abnormal retinal function associated with fenretinide, a synthetic retinoid. Arch Ophthalmol 104:69-70, 1986
39. Gross EG, Peck GL, DiGiovanna JJ: Adverse reaction to fenretinide, a synthetic retinoid. Arch Dermatol 127:1849-1850, 1991
40. Modiano MR, Dalton WS, Lippman SM, et al: Phase II study of fenretinide (N-[4-hydroxyphenyl] retinamide) in advanced breast cancer and melanoma. Invest New Drugs 8:317-319, 1990
41. Formelli F, Clerici M, Campa T, et al: Five-year administration of fenretinide: Pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 11:2036-2042, 1993
42. Doose DR MF, Stellar S, et al: Effects of meals and meal composition on the bioavailability of fenretinide. J Clin Pharmacol 32:1089-1095, 1992
43. Formelli F, Carsana R, Costa A, et al: Plasma retinol level reduction by the synthetic retinoid fenretinide: A one year follow-up study of breast cancer patients. Cancer Res 49:6149-6152, 1989
44. Peng YM, Dalton WS, Alberts DS, et al: Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients. Int J Cancer 43: 22-26, 1989
45. Lin Y, Shih WJ: Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials. Biostatistics 2:203-215, 2001
46. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477, 1993
47. Jasti BR, LoRusso PM, Parchment RE, et al: Phase I clinical trial of fenretinide (NSC374551) in advanced solid tumors. Proc Am Clin Oncol 20:122a, 2001 (abstr 485)
48. Matthay KK, Villablanca JG, Seeger RC, et al: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341:1165-1173, 1999
49. Villablanca JG, Khan AA, Avramis VI, et al: Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol 13:894-901, 1995
50. Smith MA, Adamson PC, Balis FM, et al: Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer. J Clin Oncol 10:1666-1673, 1992
51. Adamson PC, Widemann BC, Reaman GH, et al: A Phase I trial and pharmacokinetic study of 9-cis-retinoic acid (ALRT1057) in pediatric patients with refractory cancer: A joint Pediatric Oncology Branch, National Cancer Institute, and Children's Oncology Group study. Clin Cancer Res 7:2955-2957, 2001
52. Eaton HD: Chronic bovine hypo- and hypervitaminosis A and cerebrospinal fluid pressure. Am J Clin Nutr 22:1070-1080, 1969
53. Smith MA: Retinoids in cancer therapy. J Clin Oncol 10:839-864, 1992
54. Garaventa A, Luksch R, Piccolo MS, et al: Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 9:2032-2039, 2003
55. Holven KB, Natarajan V, Gundersen TE, et al: Secretion of N-(4-hydroxyphenyl) retinamide-retinol-binding protein from liver parenchymal cells: Evidence for reduced affinity of the complex for transthyretin. Int J Cancer 71:654-659, 1997
56. Mehta RR, Graves JM, Mehta RG: Metabolism of N-[4-hydroxyphenyl] retinamide (4-HPR) to N-[4-methoxyphenyl] retinamide (4-MPR) may serve as a biomarker for its efficacy against human breast cancer and melanoma cells. Eur J Cancer Clin Oncol 34:902-907, 1998
57. Gupta S ZJ, Vishnuvajjala R, Maurer BJ, et al: Product development of fenretinide, NSC 374551, intravenous emulsion formulation. Presented at the Controlled Release Society, 31st Annual Meeting, Honolulu, Hawaii, June 12-16, 2004
58. Maurer BJ, Reynolds CP, Yesair D, et al: Improved oral fenretinide delivery with novel Lym-X-Sorb TM organized lipid complex. Proc Am Assoc Cancer Res 45:148, 2004 (abstr 7112)